Hospitalized patients with HFmrEF/HFpEF and atrial fibrillation received fewer antiarrhythmics (30% vs 34%) and beta-blockers (75% vs 95%) compared to those with HFrEF.
Observational (n=1,426)
Yes
In patients hospitalized with concurrent atrial fibrillation and heart failure, the use of rhythm-control strategies is uncommon and varies significantly by heart failure subtype.
ABSTRACTBackground Patients hospitalized with atrial fibrillation (AFIB) and heart failure (HF) have high morbidity and mortality rates, yet guideline-directed management of patients hospitalized with AFIB and HF has not been well described. We aimed to characterize patients mutually enrolled into Get With The Guidelines-Atrial Fibrillation (GWTG-AFIB) and -Heart Failure (GWTG-HF) quality registries associated with in-hospital outcomes. Methods and Results Hospitalized patients enrolled in the GWTG-AFIB/GWTG-HF registries were linked by identifiers and mutual encounters. Patients were grouped by those with HF with midrange/preserved ejection fraction (HFmrEF/HFpEF) and reduced ejection fraction (HFrEF). In-hospital mortality rates, lengths of stay, and HF/AFIB quality achievements were summarized. Of 90,531 and 695,889 patient encounters in GWTG-AFIB/GWTG-HF between January 2013 and December 2019, respectively, there were 1,642 hospitalizations among 1,426 uniquely linked patients. Patients with HFmrEF/HFpEF compared with HFrEF were more often older (median age 80 vs 72 years), female (61% vs 33%), and non-Black (95% vs 84%). The lengths of stay were similar in both groups (median, 4 days); patients with HFmrEF/HFpEF compared to those with HFrEF were more likely to remain in AFIB (49% vs 39%), received fewer antiarrhythmics (30% vs 34%) or beta-blockers (75% vs 95%), and underwent fewer cardioversions (12% vs 21%), although in-hospital ablation for AFIB was infrequent in both groups. Conclusions In a contemporary cohort of hospitalized patients uniquely enrolled into both GWTG-AFIB/GWTG-HF quality registries, the use of rhythm-control strategies for atrial fibrillation was uncommon and varied by HF subtype. Implementation efforts may serve to optimize guideline recommendations for AFIB and HF.
Rao et al. (Mon,) conducted a observational in Atrial fibrillation and heart failure (n=1,426). HFmrEF/HFpEF vs. HFrEF was evaluated on In-hospital mortality rates, lengths of stay, and HF/AFIB quality achievements. Hospitalized patients with HFmrEF/HFpEF and atrial fibrillation received fewer antiarrhythmics (30% vs 34%) and beta-blockers (75% vs 95%) compared to those with HFrEF.